J&J/DePuy Charité Artificial Spinal Disc Unanimously Backed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/DePuy Spine should collect two years of postmarket follow-up data on Charité artificial lumbar disc recipients, according to FDA's Orthopaedic & Rehabilitation Devices Panel